SELLAS Life Sciences Group Inc. (SLS): Narxning daromadga nisbati
GURU.Markets tomonidan taqdim etilgan narx-sotuvlar nisbati biznesning leykoz terapiyasi muvaffaqiyatiga bog'liqligi bilan korrelyatsiya qiladi va 41.00 SELLAS Life Sciences (SLS) uchun ushbu metrikaning joriy qiymatini belgilaydi. Strategiya o'smalarga qarshi kurashish uchun peptid vaksinalarini ishlab chiqishga asoslangan. Hozirda SELLAS Life Sciences (SLS) har qanday birlashish yoki sotib olish kelishuvlarini istisno qilgan holda, to'liq ravishda o'zining pipeline klinik sinovlariga e'tibor qaratgan.
SELLAS Life Sciences (SLS) - koʻrsatkichlar kesimi va moliyaviy hisobotlar
- joriy kotirovkalar va o'rtacha qiymat prognozi:
- birja kapitallashuvi ma'lumotlari:
- emitentning balans qiymati statistikasi:
- emitentning kredit yuki va likvidlik ko'rsatkichlari:
Umumiy qarzning kapitalga nisbati koeffitsiyenti SELLAS Life Sciences|SLS - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati sellaslifesciences.com|SLS - Kompaniya qarzlari|Qarzning balans kapitallashuviga nisbati SELLAS Life Sciences Group Inc.|SLS - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz hajmi SELLAS Life Sciences|Kritik likvidlik koeffitsiyenti sellaslifesciences.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
SLS - Sof foyda|Kutilayotgan sof foyda SELLAS Life Sciences|SLS - Narx-foyda koeffitsiyenti|Kelajakdagi narx-foyda multiplikatori sellaslifesciences.com|SLS - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati SELLAS Life Sciences Group Inc.|SLS - EBITDA operatsion foydasi|So'nggi 12 oy davomida bir aksiya uchun sof foyda SELLAS Life Sciences|SLS - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik o'zgarishi sellaslifesciences.com|SLS - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun sof foydaning kutilayotgan o'sishi SELLAS Life Sciences
- emitentning tushumi va sotuvlari tafsilotlari:
Kompaniyaning fundamental tahlili:SELLAS Life Sciences Group, Inc. SLS
SELLAS Life Sciences (SLS) kompaniyasida peptid sintezining robotlashtirilishi va ma'lumotlar tahlilining avtomatlashtirilishi onkologik dori vositalarini ishlab chiqishning operatsion samaradorligini o'zgartirmoqda va texnologik stekni asosiy aktivga aylantirmoqda. Kompaniyaning tarixiy P/S koeffitsiyentini tahlil qilish orqali investor bir dollarlik daromadning bozor qiymatini aniqlaydi, bu esa kelajakdagi o'sish sur'atlari uchun haddan tashqari to'lovni aniqlash yoki institutsional investorlar tomonidan yashirin kapital to'planganini aniqlash imkonini beradi.
Raqobatdosh kompaniyalar
ONC - Sotuvga nisbatan narx|Narxning daromadga nisbati Halozyme HALO|Revolution Medicines Inc - Narxning daromadga nisbati|AAPG - Narxning daromadga nisbati|CGON: Narxning daromadga nisbati|URGN: P/S multiplikatori|bicara.com (BCAX) - P/S multiplikatori|Narxning daromadga nisbati Personalis|Erasca Inc (ERAS) - Narx/daromad koeffitsiyenti|Kapitalizatsiyaning daromadga nisbati DCTH (Delcath)|YMAB (Y-mAbs Corp) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Aura Biosciences, Inc. AURA|Candel Therapeutics Inc. - Narxning daromadga nisbati|Accuray - P/S multiplikatori|Narx/daromad koeffitsiyenti Actuate Therapeutics Inc. ACTU|CTOR: P/S multiplikatori|Narxning sotuvga nisbati HURA (TuHURA Biosciences)|TARA (Protara Therapeutics) - P/S multiplikatori|Sotuvga nisbatan narx fatetherapeutics.com FATE|Kapitalizatsiyaning daromadga nisbati WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Champions Oncology, Inc. CSBR|Narx/daromad koeffitsiyenti XBiotech Inc (XBIT)|CEL-SCI Corp - P/S multiplikatori|ostherapies.com (OSTX) - Kapitalizatsiyaning daromadga nisbati|RADX: P/S multiplikatori|ARTV - Narx/daromad koeffitsiyenti|ANL (Adlai Nortye Ltd) - P/S multiplikatori|Sotuvga nisbatan narx Veru Corporation VERU|Narxning daromadga nisbati Tempest Therapeutics (TPST)|xiliotx.com - Kapitalizatsiya va daromad nisbati|P/S multiplikatori RENB (Renovaro)|MURA - Kapitalizatsiyaning daromadga nisbati|Kairos Pharma Inc - P/S multiplikatori|Sotuvga nisbatan narx OnKure Therapeutics Inc|w2.cytomed.sg (GDTC) - Narxning daromadga nisbati|CRIS - Narx/daromad koeffitsiyenti|Narxning daromadga nisbati Apollomics Inc.|Tharimmune Inc (THAR) - Narx/daromad koeffitsiyenti|Narxning daromadga nisbati Advanced Biomed Inc (ADVB)|Narxning daromadga nisbati GNPX (Genprex Inc)|Narxning daromadga nisbati Calidi Biotherapeutics, Inc. CLDI|Narx/daromad koeffitsiyenti sunshinebiopharma.com (SBFM)|Xenetic Bio - P/S multiplikatori|Salarius Pharmaceuticals Inc (SLRX) - Kapitalizatsiyaning daromadga nisbati|PPBT: P/S multiplikatori|American Oncology Network, Inc. (AONC) - P/S multiplikatori|Narxning daromadga nisbati BeiGene, Ltd.|Kapitalizatsiya va daromad nisbati CKPT (checkpointtx.com)|P/S multiplikatori ELEV|Kapitalizatsiyaning daromadga nisbati icadmed.com ICAD|P/S multiplikatori IKNA (Ikena Oncology)|Notable Labs Corp (NTBL) - Sotuvga nisbatan narx|VIRX - Narxning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati MOR (morphosys.com)|NAYA (NAYA Biosciences Inc.) - Kapitalizatsiyaning daromadga nisbati|Ascentage Pharma Group International - Bozor kapitallashuvining daromadga nisbati
